Loreal

Savdo gʻoyalari

Treyderlarning kayfiyati

Texnik xulosa

Soatlik

Yangiliklar

Reuters - 1 kun oldin

L'Oreal, Stellantis NV, Videndum

EUROPE RESEARCH ROUNDUP-L'Oreal, Stellantis NV, Videndum Oct 4 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including L'Oreal, Stellantis NV and Videndum on Friday. HIGHLIGHTS * Gerresheimer AG GXIG.DE : Berenberg cuts target price to EUR 110 from EUR 125 * L'Oreal OREP.PA : Stifel cuts target price to EUR 440 from EUR 450 * Scor SCOR.PA : Berenberg raises to buy from hold * Stellantis NV STLAM.MI : RBC cuts to sector perform from outperfo

Reuters - 5 kun oldin

Hair relaxer class action over reimbursement for products can move forward, judge says

Hair relaxer class action over reimbursement for products can move forward, judge says By Diana Novak Jones Sept 30 (Reuters) - The judge overseeing the sprawling litigation over claims that chemical hair relaxer products made by L'Oreal USA, Revlon and others cause cancer refused to dismiss a proposed class action brought by consumers seeking reimbursement for products they say they would not have purchased had they known of the risks.

Reuters - 6 kun oldin

France considers tax increase for big companies, Le Monde reports

UPDATE 1-France considers tax increase for big companies, Le Monde reports Adds response in paragraph 9 PARIS, Sept 29 (Reuters) - France's new Prime Minister Michel Barnier is considering a temporary increase in corporate tax on the country's biggest companies .FCHI as well as a tax on share buybacks as part of efforts to plug a gaping hole in public finances, Le Monde newspaper reported on Sunday.

Reuters - 6 kun oldin

France considers tax increase for big companies, Le Monde reports

France considers tax increase for big companies, Le Monde reports PARIS, Sept 29 (Reuters) - France's new Prime Minister Michel Barnier is considering a temporary increase in corporate tax on the country's biggest companies .FCHI as well as a tax on share buybacks as part of efforts to plug a gaping hole in public finances, Le Monde newspaper reported on Sunday.

Reuters - 3 hafta oldin

L'Oreal, Evonik join $38.6 mln funding round for biotech start-up Abolis

L'Oreal, Evonik join $38.6 mln funding round for biotech start-up Abolis Sept 12 (Reuters) - L'Oreal OREP.PA has joined Abolis Biotechnologies's 35 million euro ($38.6 million) funding round alongside speciality chemicals group Evonik EVKn.DE , as part of a deal to develop bio-based ingredients for beauty products, the French cosmetics group said on Thursday.

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.